ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2016

Abstract Number: 335

High Risk of Osteoporosis and Long Term Joint Damage in Adults with a History of Juvenile Idiopathic Arthritis

Hiranda Dodanwala1, Danielle Feger1, Nicholas Longson2, Nancy J. Olsen3, Barbara E. Ostrov4,5 and Rayford R. June6, 1Medicine - Division of Rheumatology, Penn State Milton S. Hershey Medical Center, Hershey, PA, 2Johns Hopkins University, Baltimore, MD, 3Divsion of Rheumatology, Department of Medicine, Penn State MS Hershey Medical Center, Hershey, PA, 4Pediatrics, Penn State Hershey Medical Center, Hershey, PA, 5Pediatrics, Penn State Hershey Children's Hospital, Hershey, PA, 6Rheumatology, Penn State Hershey Medical Center, Hershey, PA

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2016

Date of first publication: September 28, 2016

Keywords: juvenile idiopathic arthritis (JIA), orthopaedic, osteoporosis and outcomes

Session Information

Date: Sunday, November 13, 2016

Title: Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis - Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is a heterogeneous group of chronic inflammatory arthritides. JIA is the most common cause of musculoskeletal disability in children, and greater than 1/3 of children with JIA have persistent disease into adulthood. JIA is associated with decreased bone mineral density, growth abnormalities and erosive joint damage. We aimed to determine the prevalence of clinical osteoporosis and related outcome measures in adults with a history of JIA at Penn State Hershey Medical Center.

Methods: We performed a retrospective analysis of 67 adult patients with a history of JIA, age of onset ≤ 16 years, treated at Penn State Hershey from January 1st 2013-June 1st, 2015. After medical record extraction with review by two physicians, covariates focusing on JIA and osteoporosis risk factors were recorded in a REDCap database. Clinical osteoporosis was defined as a clinical diagnosis of osteoporosis by the physician and/or fragility fracture. Standard descriptive statistics were used to calculate means, standard deviations and frequencies. Covariates were compared between subjects with and without clinical osteoporosis using nonparametric tests. Statistical significance was determined by P values of <= 0.05.

Results: Patients had a mean age of 26 years, disease duration of 19 (+/- 9.5) years and were 85% female with 67.2% having polyarticular disease. Twelve percent (8/67) had clinical osteoporosis. Clinical osteoporosis was associated with longstanding disease features including disease duration and current age (p=0.05), increased disability scores on the health assessment questionnaire (p=0.035), history of orthopedic and joint replacement surgery (p < 0.0001 for both), increased frequency of current glucocorticoid use (p=0.0052), erosive joint disease (p=0.01) and there was a trend for association with ETOH use (p=0.07). More clinical osteoporosis subjects were using calcium and vitamin D (p=0.0052), had DEXA scans ordered (p < 0.0001) and vitamin D levels within the past year. No significant difference was observed for JIA classification subtype, gender, BMI, tobacco use, current or history of methotrexate or Tumor Necrosis Factor α-inhibitor use.

Conclusion: Adult patients with a history of JIA have a high prevalence of clinical osteoporosis, which is associated with both long standing JIA and glucocorticoid use. Adult Rheumatology providers should have increased awareness of poor osteoporotic outcomes in this unique patient population. Table: Univariate Analysis of Osteoporotic vs Non-Osteoporotic subjects with a History of JIA

Item Overall Mean±SD (N)/%(Ratio) Osteoporosis Mean±SD (N)/%(Ratio) No osteoporosis Mean±SD (N)/%(Ratio) p-value
Demographics and JIA Disease Features
Age 26.09 ± 8.177 (67) 38.76 ± 26.49 (8) 22.75 ±7.34 (59) 0.0454*
Age at diagnosis 7.03 ± 4.90 (66) 5.47 ± 3.62 (8) 5.68 ± 8.53 (58) 0.9922
Disease Duration 18.99 ± 9.48 (66) 31.10 ± 27.08 (8) 18.28 ± 10.90 (58) 0.0483*
BMI 28.88 ± 9.11 (67) 23.09 ± 5.44 (8) 27.49 ± 10.57 (59) 0.1593
Gender (% Female) 85% (57/67) 75% (6/8) 86.4% (51/59) 0.3413
Current tobacco use 7.6% (5/66) 12.50% (1/8) 6.90% (4/58) 0.4873
Current ETOH use 43.3% (26/60) 75.00% (6/8) 38.46% (20/52) 0.0669
HAQ 0.3966 ± 0.55 (58/67) 0.6875 ± 1.0625 (8) 0.0625 ± 0.6250 (50) 0.0351*
RF positive (%) 24.4% (10/41) 40.00% (2/5) 22.22% (8/36) 0.5801
Current Glucocorticoid Use 11.9% (8/67) 50.0% (4/8) 6.8% (4/59) 0.0052*
Bone Outcomes
Osteopenia on X rays 50.9% (27/53) 100.00% (7/7) 43.48% (20/46 ) 0.0100*
Erosions on X rays 50.9% (27/53) 100.00% (7/7) 43.48% (20/46) 0.0100*
Erosions and Osteopenia X-rays 34.0% (18/53) 100.00% (7/7) 23.91% (11/46) 0.0002*
Any Orthopedic Surgery 32.8% (22/67) 100.00% (8/8) 23.73% (14/59) <0.0001*
Joint Replacement Surgery 13.4% (9/67) 75.00% (6/8) 5.08% (3/59) <0.0001*
Fractures (excluding fragility) 20.9% (14/67) 50.00% (4/8) 16.95% (10/59) 0.0528

Disclosure: H. Dodanwala, None; D. Feger, None; N. Longson, None; N. J. Olsen, None; B. E. Ostrov, None; R. R. June, Pfizer Inc, 2.

To cite this abstract in AMA style:

Dodanwala H, Feger D, Longson N, Olsen NJ, Ostrov BE, June RR. High Risk of Osteoporosis and Long Term Joint Damage in Adults with a History of Juvenile Idiopathic Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/high-risk-of-osteoporosis-and-long-term-joint-damage-in-adults-with-a-history-of-juvenile-idiopathic-arthritis/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/high-risk-of-osteoporosis-and-long-term-joint-damage-in-adults-with-a-history-of-juvenile-idiopathic-arthritis/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology